AbbVie Shares Advance Following Raised 2026 Guidance and Pipeline Wins
AbbVie lifted its annual revenue forecast to $67.8 billion after strong third-quarter results and announced several late-stage clinical and regulatory advancements across its portfolio.
AbbVie Inc. shares have climbed 4.5% over the past month, buoyed by third-quarter financial results that exceeded expectations and led to higher full-year revenue projections. Third-quarter adjusted earnings per share reached $3.82, marking a 105.4% increase from the prior-year period. Total net revenues grew more than 10% to $17.4 billion, beating internal estimates by $200 million as nine different products logged double-digit expansion. Following the quarter, the drugmaker raised its 2026 revenue guidance to $67.8 billion from $67.6 billion, marking its third upward revision of the year.
The company continues to offset patent exclusivity losses on its former top seller, Humira, through growth in its primary immunology products. Skyrizi posted third-quarter revenue of $5.78 billion, representing operational growth of 22.9%, while Rinvoq generated $2.71 billion with an increase of 24.3%. For the full year 2026, AbbVie projects combined revenue from both therapies to surpass $32 billion. In October, the company obtained regulatory clearance for an under-the-skin induction regimen for Skyrizi in Crohn's disease, and Rinvoq secured approval in the European Union for vitiligo and alopecia areata in July 2026.
Beyond immunology, AbbVie is seeing momentum in its neuroscience and oncology divisions. First nine months 2026 sales for Parkinson's therapy Vyalev reached $743 million, which the business anticipates will achieve blockbuster status in 2026. The FDA also cleared oral Parkinson's treatment Juvmo in September 2026. In late-stage developments, the company announced favorable Phase 3 results for Qulipta in preventing migraines, while investigational multiple myeloma drug etentamig was submitted for a biologics license application to the FDA.
Additionally, AbbVie presented data on November 08, 2026, from two clinical studies examining patients receiving GLP-1 weight-loss medications. Participants who underwent cosmetic procedures using Botox and hyaluronic acid fillers demonstrated marked gains in facial satisfaction, averaging increases of 42.4 points and 39.6 points in respective trials. In clinical immunology, lutikizumab achieved its primary endpoint in the Phase 3 INTREPID trial for hidradenitis suppurativa, recording a 31.4% response rate versus 23.4% on placebo.
Valuation assessments among market observers remain mixed. Simply Wall St reported that AbbVie's cash flows over the last twelve months reached about $18.9 billion, suggesting intrinsic value above its share price of $293.89. In contrast, GuruFocus calculated a GF Value™ of $229.04, indicating the stock was modestly overvalued at $291.31, while also noting a dividend yield of 2.26% and a 74% payout ratio alongside $17.7 million in net insider selling over the past 12 months.